Inflammasomes, the cardinal pathology mediators are activated by pathogens, allergens and mutagens: A critical review with focus on NLRP3

Biomedicine and Pharmacotherapy

Volumn 92, Issue , 2017, Pages 819-825

  Patel, Seema ^a  

^a SAN DIEGO STATE UNIVERSITY   (United States)

Author keywords

Caspase; DAMPs; IL 18; IL 1 ; Inflammasomes; NLRP3; PAMPs

Indexed keywords

ALLERGEN; CASPASE 11; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MUTAGENIC AGENT;

CANCER THERAPY; ENZYME ACTIVATION; HUMAN; MEDIATOR; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; BIOLOGICAL MODEL; METABOLISM; NEOPLASM;

ALLERGENS; ANIMALS; HUMANS; INFLAMMASOMES; MODELS, BIOLOGICAL; MUTAGENS; NEOPLASMS; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN;

EID: 85020269002     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2017.05.126     Document Type: Review

References (118)

1. Tracy, R.P., The five cardinal signs of inflammation: calor, dolor, rubor, tumor … and penuria (apologies to aulus cornelius celsus, de medicina, c. A. D. 25). J. Gerontol. A: Biol. Sci. Med. Sci. 61 (2006), 1051–1052.
2. Wilgus, T.A., Roy, S., McDaniel, J.C., Neutrophils and wound repair: positive actions and negative reactions. Adv. Wound Care 2 (2013), 379–388, 10.1089/wound.2012.0383.
3. Zhao, G., Usui, M.L., Lippman, S.I., et al. Biofilms and inflammation in chronic wounds. Adv. Wound Care 2 (2013), 389–399, 10.1089/wound.2012.0381.
4. Kim, R.Y., Pinkerton, J.W., Gibson, P.G., et al. Inflammasomes in COPD and neutrophilic asthma. Thorax 70 (2015), 1199–1201, 10.1136/thoraxjnl-2014-206736.
5. Wu, C.-Y., Yang, H.-Y., Yao, T.-C., et al. Serum IL-18 as biomarker in predicting long-term renal outcome among pediatric-onset systemic lupus erythematosus patients. Medicine (Baltim.), 95, 2016, e5037, 10.1097/MD.0000000000005037.
6. Shao, B.-Z., Xu, Z.-Q., Han, B.-Z., et al. NLRP3 inflammasome and its inhibitors: a review. Front. Pharmacol., 6, 2015, 262, 10.3389/fphar.2015.00262.
7. Kingsbury, S.R., Conaghan, P.G., McDermott, M.F., The role of the NLRP3 inflammasome in gout. J. Inflamm. Res. 4 (2011), 39–49, 10.2147/JIR.S11330.
8. Sayan, M., Mossman, B.T., The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases. Part. Fibre Toxicol., 13, 2016, 51, 10.1186/s12989-016-0162-4.
9. González-Navajas, J.M., Inflammasome activation in decompensated liver cirrhosis. World J. Hepatol. 8 (2016), 207–210, 10.4254/wjh.v8.4.207.
10. Galkina, E., Ley, K., Immune and inflammatory mechanisms of atherosclerosis(*). Annu. Rev. Immunol. 27 (2009), 165–197, 10.1146/annurev.immunol.021908.132620.
11. Rakoff-Nahoum, S., Why cancer and inflammation?. Yale J. Biol. Med. 79 (2006), 123–130.
12. Peebles, K.A., Lee, J.M., Mao, J.T., et al. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev. Anticancer Ther. 7 (2007), 1405–1421, 10.1586/14737140.7.10.1405.
13. Müzes, G., Sipos, F., Inflammasome, inflammation and cancer: an interrelated pathobiological triad. Curr. Drug Targets 16 (2015), 249–257.
14. Conley, S.M., Abais, J.M., Boini, K.M., Li, P.-L., Inflammasome activation in chronic glomerular diseases. Curr. Drug Targets, 2016 PMID: 27538510.
15. Anders, H.-J., Of inflammasomes and alarmins: IL-1β and IL-1α in kidney disease. J. Am. Soc. Nephrol. 27 (2016), 2564–2575, 10.1681/ASN.2016020177.
16. Sakai, N., Furuichi, K., Wada, T., Inhibition of NLRP3 inflammasome as a therapeutic intervention in crystal-induced nephropathy. Kidney Int. 90 (2016), 466–468, 10.1016/j.kint.2016.05.003.
17. Dantzer, R., O'Connor, J.C., Freund, G.G., et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008), 46–56, 10.1038/nrn2297.
18. Wong, M.-L., Inserra, A., Lewis, M.D., et al. Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition. Mol. Psychiatry 21 (2016), 797–805, 10.1038/mp.2016.46.
19. Guerriero, F., Sgarlata, C., Francis, M., et al. Neuroinflammation, immune system and Alzheimer disease: searching for the missing link. Aging Clin. Exp. Res., 2016, 10.1007/s40520-016-0637-z PMID: 27718173.
20. Kundu, J.K., Surh, Y.-J., Inflammation: gearing the journey to cancer. Mutat. Res. 659 (2008), 15–30, 10.1016/j.mrrev.2008.03.002.
21. Khansari, N., Shakiba, Y., Mahmoudi, M., Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat. Inflamm. Allergy Drug Discov. 3 (2009), 73–80.
22. Jorgensen, I., Lopez, J.P., Laufer, S.A., Miao, E.A., IL-1β, IL-18, and eicosanoids promote neutrophil recruitment to pore-induced intracellular traps following pyroptnosis. Eur J Immunol. 46 (2016), 2761–2766, 10.1002/eji.201646647.
23. Zhang, J.-M., An, J., Cytokines, inflammation, and pain. Int. Anesthesiol. Clin. 45 (2007), 27–37, 10.1097/AIA.0b013e318034194e.
24. Page-McCaw, A., Ewald, A.J., Werb, Z., Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8 (2007), 221–233, 10.1038/nrm2125.
25. Ricciotti, E., FitzGerald, G.A., Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 986–1000, 10.1161/ATVBAHA.110.207449.
26. Roberts, L.L., Robinson, C.M., Mycobacterium tuberculosis infection of human dendritic cells decreases integrin expression, adhesion and migration to chemokines. Immunology 141 (2014), 39–51, 10.1111/imm.12164.
27. Martillo, M.A., Nazzal, L., Crittenden, D.B., The crystallization of monosodium urate. Curr. Rheumatol. Rep., 16, 2014, 400, 10.1007/s11926-013-0400-9.
28. Pillon, N.J., Chan, K.L., Zhang, S., et al. Saturated fatty acids activate caspase-4/-5 in human monocytes, triggering IL1β and IL18 release. Am. J. Physiol. Endocrinol. Metab. 311 (2016), 825–835, 10.1152/ajpendo.00296.2016 ajpendo.00296.
29. Khansari, N., Shakiba, Y., Mahmoudi, M., Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat. Inflamm. Allergy Drug Discov. 3 (2009), 73–80.
30. Jain, A., Kaczanowska, S., Davila, E., IL-1 receptor-associated kinase signaling and its role in inflammation, cancer progression, and therapy resistance. Front. Immunol., 5, 2014, 553, 10.3389/fimmu.2014.00553.
31. Wang, S., Wang, Z., Gu, Y., et al. Toxoplasma gondii mitogen-activated protein kinases are associated with inflammasome activation in infected mice. Microbes Infect. 18 (2016), 696–700, 10.1016/j.micinf.2016.07.004.
32. Kolb, R., Liu, G.-H., Janowski, A.M., et al. Inflammasomes in cancer: a double-edged sword. Protein Cell 5 (2014), 12–20, 10.1007/s13238-013-0001-4.
33. Guo, H., Callaway, J.B., Ting, J.P.-Y., Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 21 (2015), 677–687, 10.1038/nm.3893.
34. Tőzsér, J., Benkő, S., Natural compounds as regulators of NLRP3 inflammasome-mediated IL-1β production. Mediat. Inflamm., 2016, 5460302, 10.1155/2016/5460302.
35. Verma, V., Dhanda, R.S., Møller, N.F., Yadav, M., Inflammasomes and their role in innate immunity of sexually transmitted infections. Front. Immunol., 7, 2016, 540, 10.3389/fimmu.2016.00540.
36. Kawai, T., Akira, S., The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 21 (2009), 317–337, 10.1093/intimm/dxp017.
37. Liu, D., Rhebergen, A.M., Eisenbarth, S.C., Licensing adaptive immunity by NOD-Like receptors. Front. Immunol., 4, 2013, 486, 10.3389/fimmu.2013.00486.
38. He, Y., Hara, H., Núñez, G., Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem. Sci. 41 (2016), 1012–1021, 10.1016/j.tibs.2016.09.002.
39. Franchi, L., Eigenbrod, T., Muñoz-Planillo, R., Nuñez, G., The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat. Immunol. 10 (2009), 241–247, 10.1038/ni.1703.
40. Furman, D., Chang, J., Lartigue, L., et al. Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nat. Med. 23 (2017), 174–184, 10.1038/nm.4267.
41. Davis, B.K., Wen, H., Ting, J.P.-Y., The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu. Rev. Immunol. 29 (2011), 707–735, 10.1146/annurev-immunol-031210-101405.
42. Loukovaara, S., Piippo, N., Kinnunen, K., et al. NLRP3 inflammasome activation is associated with proliferative diabetic retinopathy. Acta Ophthalmol., 2017, 10.1111/aos.13427.
43. Martinon, F., Mayor, A., Tschopp, J., The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27 (2009), 229–265, 10.1146/annurev.immunol.021908.132715.
44. Kanneganti, T.-D., The inflammasome: firing up innate immunity. Immunol. Rev. 265 (2015), 1–5, 10.1111/imr.12297.
45. Cassel, S.L., Sutterwala, F.S., Sterile inflammatory responses mediated by the NLRP3 inflammasome. Eur. J. Immunol. 40 (2010), 607–611, 10.1002/eji.200940207.
46. Kayagaki, N., Warming, S., Lamkanfi, M., et al. Non-canonical inflammasome activation targets caspase-11. Nature 479 (2011), 117–121, 10.1038/nature10558.
47. Shi, J., Zhao, Y., Wang, Y., et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514 (2014), 187–192, 10.1038/nature13683.
48. Triantafilou, K., Kar, S., van Kuppeveld, F.J.M., Triantafilou, M., Rhinovirus-induced calcium flux triggers NLRP3 and NLRC5 activation in bronchial cells. Am. J. Respir. Cell Mol. Biol. 49 (2013), 923–934, 10.1165/rcmb.2013-0032OC.
49. Mamik, M.K., Hui, E., Branton, W.G., et al. HIV-1 viral protein R activates NLRP3 inflammasome in microglia: implications for HIV-1 associated neuroinflammation. J. Neuroimmune Pharmacol. 12 (2016), 233–248, 10.1007/s11481-016-9708-3.
50. Broz, P., Monack, D.M., Molecular mechanisms of inflammasome activation during microbial infections. Immunol. Rev. 243 (2011), 174–190, 10.1111/j.1600-065X.2011.01041.x.
51. Torres, I.M., Patankar, Y.R., Shabaneh, T.B., et al. Acidosis potentiates the host proinflammatory interleukin-1β response to Pseudomonas aeruginosa infection. Infect. Immun. 82 (2014), 4689–4697, 10.1128/IAI.02024-14.
52. Ablasser, A., Dorhoi, A., Inflammasome activation and function during infection with mycobacterium tuberculosis. Curr. Top. Microbiol. Immunol. 397 (2016), 183–197, 10.1007/978-3-319-41171-2_9.
53. Crowley, S.M., Knodler, L.A., Vallance, B.A., Salmonella and the inflammasome: battle for intracellular dominance. Curr. Top. Microbiol. Immunol. 397 (2016), 43–67, 10.1007/978-3-319-41171-2_3.
54. Philip, N.H., Zwack, E.E., Brodsky, I.E., Activation and evasion of inflammasomes by yersinia. Curr. Top. Microbiol. Immunol. 397 (2016), 69–90, 10.1007/978-3-319-41171-2_4.
55. Rabes, A., Suttorp, N., Opitz, B., Inflammasomes in pneumococcal infection: innate immune sensing and bacterial evasion strategies. Curr. Top. Microbiol. Immunol. 397 (2016), 215–227, 10.1007/978-3-319-41171-2_11.
56. Theisen, E., Sauer, J.-D., Listeria monocytogenes and the inflammasome: from cytosolic bacteriolysis to tumor immunotherapy. Curr. Top. Microbiol. Immunol. 397 (2016), 133–160, 10.1007/978-3-319-41171-2_7.
57. Wallet, P., Lagrange, B., Henry, T., Francisella inflammasomes: integrated responses to a cytosolic stealth bacterium. Curr. Top. Microbiol. Immunol. 397 (2016), 229–256, 10.1007/978-3-319-41171-2_12.
58. Hoss, F., Budden, C.F., Latz, E., IRGB10 exposes bacteria's intimate secrets. Dev. Cell 39 (2016), 7–8, 10.1016/j.devcel.2016.09.026.
59. Ding, J., Wang, K., Liu, W., et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 535 (2016), 111–116, 10.1038/nature18590.
60. Liu, X., Zhang, Z., Ruan, J., et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 535 (2016), 153–158, 10.1038/nature18629.
61. Kayagaki, N., Stowe, I.B., Lee, B.L., Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526 (2015), 666–671, 10.1038/nature15541.
62. Shi, J., Zhao, Y., Wang, K., et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526 (2015), 660–665, 10.1038/nature15514.
63. Jorgensen, I., Zhang, Y., Krantz, B.A., Miao, E.A., Pyroptosis triggers pore-induced intracellular traps (PITs) that capture bacteria and lead to their clearance by efferocytosis. J. Exp. Med. 213 (2016), 2113–2328, 10.1084/jem.20151613.
64. de Haan, J.J., Smeets, M.B., Pasterkamp, G., Arslan, F., Danger signals in the initiation of the inflammatory response after myocardial infarction. Mediat. Inflamm., 2013, 206039, 10.1155/2013/206039.
65. Wemmie, J.A., Taugher, R.J., Kreple, C.J., Acid-sensing ion channels in pain and disease. Nat. Rev. Neurosci. 14 (2013), 461–471, 10.1038/nrn3529.
66. Li, W.-G., Xu, T.-L., Acid-sensing ion channels: a novel therapeutic target for pain and anxiety. Curr. Pharm. Des. 21 (2015), 885–894.
67. Li, M.-H., Leng, T.-D., Feng, X.-C., et al. Modulation of acid-sensing ion channel 1a by intracellular pH and its role in ischemic stroke. J. Biol. Chem. 291 (2016), 18370–18383, 10.1074/jbc.M115.713636.
68. Rajamäki, K., Nordström, T., Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome. J. Biol. Chem. 288 (2013), 13410–13419, 10.1074/jbc.M112.426254.
69. Wang, Y.-C., Li, W.-Z., Wu, Y., et al. Acid-sensing ion channel 1a contributes to the effect of extracellular acidosis on NLRP1 inflammasome activation in cortical neurons. J. Neuroinflammation, 12, 2015, 246, 10.1186/s12974-015-0465-7.
70. Grace, P.M., Strand, K.A., Galer, E.L., et al. Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activation. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E3441–E3450, 10.1073/pnas.1602070113.
71. Yu, S.-J., Liao, E.-C., Sheu, M.-L., et al. Cell-penetrating peptide derived from human eosinophil cationic protein inhibits mite allergen Der p 2 induced inflammasome activation. PLoS One, 10, 2015, e0121393, 10.1371/journal.pone.0121393.
72. Cheong, S.H., Choi, Y.W., Choi, H.Y., Byun, J.Y., Nickel and cobalt release from jewellery and metal clothing items in Korea. Contact Dermat. 70 (2014), 11–18, 10.1111/cod.12141.
73. Li, X., Zhong, F., Nickel induces interleukin-1β secretion via the NLRP3-ASC—caspase-1 pathway. Inflammation 37 (2014), 457–466, 10.1007/s10753-013-9759-z.
74. Hirota, J.A., Gold, M.J., Hiebert, P.R., et al. The nucleotide-binding domain, leucine-rich repeat protein 3 inflammasome/IL-1 receptor I axis mediates innate, but not adaptive, immune responses after exposure to particulate matter under 10 μm. Am. J. Respir. Cell Mol. Biol. 52 (2015), 96–105, 10.1165/rcmb.2014-0158OC.
75. de Punder, K., Pruimboom, L., The dietary intake of wheat and other cereal grains and their role in inflammation. Nutrients 5 (2013), 771–787, 10.3390/nu5030771.
76. Jang, Y., Lee, A.Y., Jeong, S.-H., et al. Chlorpyrifos induces NLRP3 inflammasome and pyroptosis/apoptosis via mitochondrial oxidative stress in human keratinocyte HaCaT cells. Toxicology 338 (2015), 37–46, 10.1016/j.tox.2015.09.006.
77. Cheng, C.-J., Kuo, E., Huang, C.-L., Extracellular potassium homeostasis: insights from hypokalemic periodic paralysis. Semin. Nephrol. 33 (2013), 237–247, 10.1016/j.semnephrol.2013.04.004.
78. Katsnelson, M.A., Rucker, L.G., Russo, H.M., Dubyak, G.R., K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling. J. Immunol. 194 (2015), 3937–3952, 10.4049/jimmunol.1402658.
79. Moon, J.-S., Nakahira, K., Chung, K.-P., et al. NOX4-dependent fatty acid oxidation promotes NLRP3 inflammasome activation in macrophages. Nat. Med. 22 (2016), 1002–1012, 10.1038/nm.4153.
80. Wang, L., Chen, Y., Li, X., et al. Enhancement of endothelial permeability by free fatty acid through lysosomal cathepsin B-mediated Nlrp3 inflammasome activation. Oncotarget 7 (2016), 73229–73241, 10.18632/oncotarget.12302.
81. Yanguas, S.C., Willebrords, J., Johnstone, S.R., et al. Pannexin1 as mediator of inflammation and cell death. Biochim. Biophys. Acta 1864 (2016), 51–61, 10.1016/j.bbamcr.2016.10.006.
82. Latz, E., Xiao, T.S., Stutz, A., Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13 (2013), 397–411, 10.1038/nri3452.
83. Abderrazak, A., Syrovets, T., Couchie, D., et al. NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol. 4 (2015), 296–307, 10.1016/j.redox.2015.01.008.
84. Próchnicki, T., Mangan, M.S., Latz, E., Recent insights into the molecular mechanisms of the NLR inflammasome activation. F1000Research, 2016, 10.12688/f1000research.8614.1.
85. Jo, E.-K., Kim, J.K., Shin, D.-M., Sasakawa, C., Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol. Immunol. 13 (2016), 148–159, 10.1038/cmi.2015.95.
86. Man, S.M., Kanneganti, T.-D., Regulation of inflammasome activation. Immunol. Rev. 265 (2015), 6–21, 10.1111/imr.12296.
87. Mortimer, L., Moreau, F., MacDonald, J.A., Chadee, K., NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations. Nat. Immunol. 17 (2016), 1176–1186, 10.1038/ni.3538.
88. Dinarello, C.A., Simon, A., van der Meer, J.W.M., Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11 (2012), 633–652, 10.1038/nrd3800.
89. Song, C., He, L., Zhang, J., et al. Fluorofenidone attenuates pulmonary inflammation and fibrosis via inhibiting the activation of NALP3 inflammasome and IL-1β/IL-1R1/MyD 88/NF-κB pathway. J. Cell. Mol. Med. 20 (2016), 2064–2077, 10.1111/jcmm.12898.
90. Hwang, I., Lee, E., Jeon, S.-A., Yu, J.-W., Histone deacetylase 6 negatively regulates NLRP3 inflammasome activation. Biochem. Biophys. Res. Commun. 467 (2015), 973–978, 10.1016/j.bbrc.2015.10.033.
91. Nurmi, K., Kareinen, I., Virkanen, J., et al. Hemin and cobalt protoporphyrin inhibit NLRP3 inflammasome activation by enhancing autophagy: a novel mechanism of inflammasome regulation. J. Innate Immun. 9 (2017), 65–82, 10.1159/000448894.
92. Zorman, J., Sušjan, P., Hafner-Bratkovič, I., Shikonin suppresses NLRP3 and AIM2 inflammasomes by direct inhibition of caspase-1. PLoS One, 11, 2016, e0159826, 10.1371/journal.pone.0159826.
93. Qiu, J., Wang, M., Zhang, J., et al. The neuroprotection of Sinomenine against ischemic stroke in mice by suppressing NLRP3 inflammasome via AMPK signaling. Int. Immunopharmacol. 40 (2016), 492–500, 10.1016/j.intimp.2016.09.024.
94. Ka, S.-M., Lin, J.-C., Lin, T.-J., et al. Citral alleviates an accelerated and severe lupus nephritis model by inhibiting the activation signal of NLRP3 inflammasome and enhancing Nrf2 activation. Arthritis Res. Ther., 17, 2015, 331, 10.1186/s13075-015-0844-6.
95. Rajanbabu, V., Galam, L., Fukumoto, J., et al. Genipin suppresses NLRP3 inflammasome activation through uncoupling protein-2. Cell. Immunol. 297 (2015), 40–45, 10.1016/j.cellimm.2015.06.002.
96. Han, J.-W., Shim, D.-W., Shin, W.-Y., et al. Anti-inflammatory effect of emodin via attenuation of NLRP3 inflammasome activation. Int. J. Mol. Sci. 16 (2015), 8102–8109, 10.3390/ijms16048102.
97. Lee, J., Ahn, H., Hong, E.-J., et al. Sulforaphane attenuates activation of NLRP3 and NLRC4 inflammasomes but not AIM2 inflammasome. Cell. Immunol. 306–307 (2016), 53–60, 10.1016/j.cellimm.2016.07.007.
98. Dagenais, M., Saleh, M., Linking cancer-induced Nlrp3 inflammasome activation to efficient NK cell-mediated immunosurveillance. Oncoimmunology, 5, 2016, e1129484, 10.1080/2162402X.2015.1129484.
99. Nicolson, G.L., Menter, D.G., Trophic factors and central nervous system metastasis. Cancer Metastasis Rev. 14 (1995), 303–321.
100. de Sá, D.C., Festa, C., Inflammasomes and dermatology. An. Bras. Dermatol. 91 (2016), 566–578, 10.1590/abd1806-4841.20165577.
101. Wang, H., Wang, Y., Du, Q., et al. Inflammasome-independent NLRP3 is required for epithelial-mesenchymal transition in colon cancer cells. Exp. Cell Res. 342 (2016), 184–192, 10.1016/j.yexcr.2016.03.009.
102. Wang, Y., Kong, H., Zeng, X., et al. Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells. Oncol. Rep. 35 (2016), 2053–2064, 10.3892/or.2016.4569.
103. Cao, S., Liu, P., Zhu, H., et al. Extracellular acidification acts as a key modulator of neutrophil apoptosis and functions. PLoS One, 10, 2015, e0137221, 10.1371/journal.pone.0137221.
104. Panchanathan, R., Liu, H., Choubey, D., Hypoxia primes human normal prostate epithelial cells and cancer cell lines for the NLRP3 and AIM2 inflammasome activation. Oncotarget 7 (2016), 28183–28194, 10.18632/oncotarget.8594.
105. Blakemore, J., Naftolin, F., Aromatase: contributions to physiology and disease in women and men. Physiology (Bethesda) 31 (2016), 258–269, 10.1152/physiol.00054.2015.
106. Demura, M., Martin, R.M., Shozu, M., et al. Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene. Hum. Mol. Genet. 16 (2007), 2529–2541, 10.1093/hmg/ddm145.
107. Izawa, M., Inoue, M., Osaki, M., et al. Cytochrome P450 aromatase gene (CYP19) expression in gastric cancer. Gastric Cancer 11 (2008), 103–110, 10.1007/s10120-008-0463-x.
108. Patel, S., Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: a comprehensive review. J. Steroid Biochem. Mol. Biol. 168 (2017), 19–25, 10.1016/j.jsbmb.2017.01.009.
109. Patel, S., A critical review on serine protease: key immune manipulator and pathology mediator. Allergol. Immunopathol. (Madr.), 2017, 10.1016/j.aller.2016.10.011.
110. Rani, A., Patel, S., Goyal, A., Chondroitin sulfate (CS) lyases: structure, function and application in therapeutics. Curr. Protein Pept. Sci., 2017.
111. Patel, S., Goyal, A., Chitin and chitinase: role in pathogenicity, allergenicity and health. Int. J. Biol. Macromol. 97 (2017), 331–338, 10.1016/j.ijbiomac.2017.01.042.
112. Rajamäki, K., Nordström, T., Nurmi, K., et al. Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome. J. Biol. Chem. 288 (2013), 13410–13419, 10.1074/jbc.M112.426254.
113. McCarty, M.F., Whitaker, J., Manipulating tumor acidification as a cancer treatment strategy. Altern. Med. Rev. 15 (2010), 264–272.
114. Wojtkowiak, J.W., Verduzco, D., Schramm, K.J., Gillies, R.J., Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol. Pharmaceutics 8 (2011), 2032–2038, 10.1021/mp200292c.
115. Kato, Y., Ozawa, S., Miyamoto, C., et al. Acidic extracellular microenvironment and cancer. Cancer Cell Int., 13, 2013, 89, 10.1186/1475-2867-13-89.
116. Peppicelli, S., Bianchini, F., Calorini, L., Extracellular acidity, a “reappreciated” trait of tumor environment driving malignancy: perspectives in diagnosis and therapy. Cancer Metastasis Rev. 33 (2014), 823–832, 10.1007/s10555-014-9506-4.
117. Deswaerte, V., Ruwanpura, S.M., Jenkins, B.J., Transcriptional regulation of inflammasome-associated pattern recognition receptors, and the relevance to disease pathogenesis. Mol. Immunol., 2016, 10.1016/j.molimm.2016.09.023.
118. El Ali, Z., Gerbeix, C., Hemon, P., et al. Allergic skin inflammation induced by chemical sensitizers is controlled by the transcription factor Nrf2. Toxicol. Sci. 134 (2013), 39–48, 10.1093/toxsci/kft084.